Pioneering an approach to psychiatric drug development which matches the right patient with the right drug based on AI-derived brain biomarkers. Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.
Market
Information Technology
Coinvestors
Alkeon Capital,Apeiron Presight Capital Fund II,Harrison Metal,Apeiron Investment Group